Abstract
Matrine is an alkaloid obtained primarily from roots of Sophora flavescens. Ait. (Leguminosae), an herb used in traditional Chinese medicine to treat a range of disease. So far, the underlying molecular mechanism for the therapeutic effects of matrine has been poorly understood. In this work, we investigated the effects of matrine on tyrosine protein phosphorylation in human cells through immunoblotting. In bcr/abl-positive K562 cells, tyrosine phosphorylations of several proteins are altered in both time-and dose-dependent manners. Such alternations are distinct from those induced by the bcr/abl-targeting inhibitor STI571 and can be blocked by the later. The treatment of bcr/abl-negative lymphocytic and myeloid cell lines by matrine produced different patterns. In Raji cells, the tyrosine phosphorylation was the only protein affected. In U937 cells, no changes were observed. The findings in this work protein the first piece of evidence that matrine can alter the cellular signal transduction network at a molecular level. The observed changes in tyrosine phosphorylation of specific proteins provide important clues for uncovering the molecular mechanism of the therapeutic effects of matrine.
Introduction
Sophora flavescens. Ait. (Leguminosae) (SF) is the dry root of a leguminous plant growing in China, Japan, and some European countries. It is commonly used in traditional Chinese medicine to treat a range of disease, including cancer (Xu et al., Citation1998), viral hepatitis (Long et al., Citation2004), cardiac arrhythmia (Li et al., Citation2000), and skin diseases (Zhang, Citation1996). Matrine (C15H24N2O) and oxymatrine (C15H24N2O2), so far uniquely found only in Sophora. species, are the major alkaloid components in this herb. These compounds are believed to be the main contributors to the various therapeutic activities of SF (Niu, Citation1997).
From clinical studies, a diverse range of physiological and pharmacological effects of matrine have been reported, including declined viral load and reduced liver damage in viral hepatitis (Zhang et al., Citation2001; Liu et al., Citation2003) and inhibited tumor growth and reinforced immune functions in cancer therapy (Ma et al., Citation1996). Matrine can also counteract heart arrhythmia in various contexts (Zhang et al., Citation1990; Ai et al., Citation2001). Reportedly, the same compound combined with other drugs can be effective in the treatment of a number of skin diseases (Ding et al., Citation2002).
Although widely appreciated, the above therapeutic effects of matrine have been so far poorly understood in terms of their underlying mechanisms. Studies at the cellular level should be able to shed light on this issue. In a previous study, we discovered that a crude mixture of SF at a dose of 12 mg/ml (w/v) leads to growth inhibition and multilineage differentiation in human erythroleukemia K562 cell line (Qin et al., Citation1994). Furthermore, we found that pure matrine (with 99% purity detected by HPLC) at 0.1 mg/ml leads to proliferation inhibition and erythroid differentiation in K562 cells (Zhang et al., Citation2001).
K562 is a bcr/abl-positive cell line established from chronic myelogenous leukemia (CML) in blast crisis (Lozzio et al., Citation1975). The bcr/abl fusion oncogene, derived from Philadelphia chromosome (Ph +) (Nowell et al., Citation1960), which is the hallmark of diseases including nearly all cases of chronic myelogenous leukemia (CML) (Cortes et al., Citation1995) and one-third of cases of adult acute lymphoblastic leukemia (ALL) (Clark et al., Citation1988), encodes a chimeric protein with constitutive tyrosine kinase activity (Dhut et al., Citation1990). This chimeric protein with a deregulated kinase plays a central role in malignant transformation (Lugo et al., Citation1990) and leukemogenesis (Daley et al., Citation1990; Heisterkamp et al., Citation1990) and has become a target for the therapeutic drugs (Szczylik et al., Citation1991). Clinical trials have proven that the Abl kinase inhibitor STI571 (Druker et al., Citation1996) is efficacious and safe for chronic phase CML and ALL with Ph + (Druker et al., Citation2001; Kantarjian et al., Citation2002), although molecular resistance is frequently observed and the duration of remission is limited in CML blast crisis (Mahon et al., Citation2000; Gorre et al., Citation2001; Roumiantsev et al., Citation2002).
To obtain insight into possible cellular mechanisms of the pharmacological effects of matrine, we investigated the effects of matrine on tyrosine phosphorylation in the bcr/abl-positive K562 cell line both with and without STI571. For comparisons, the effects of both matrine and STI571 on tyrosine phosphorylation in bcr/abl-negative lymphocytic (Raji) and myeloid (U937) cell lines were also investigated.
Materials and Methods
Cells
K562, U937, and Raji cell lines were cultured separately in RPMI 1640 supplemented with penicillin, streptomycin, and 10% FCS. They were maintained in a 37°C, 5% CO2, fully humidified incubator, passed twice weekly.
Reagents
Matrine was purchased from Xian Botany Garden of Shanxi Province, China, and prepared as a 10 mg/ml stock solution in sterile H2O. STI571 was provided by Novartis Pharmaceuticals (Switzerland), and prepared as a 5 mM stock solution in sterile H2O.
Experimental format
Logarithmically growing cells were collected, the cells were diluted to final concentration of 2 × 105 cells/ml, to which were added the designated drugs, and the cells were placed in the incubator for intervals. The final concentration for matrine was 0.1, 0.2, 0.5 mg/ml, respectively, and for STI571, 0.1, 0.25, 0.5, 1.0 µM. At the end of the incubation period, cells were transferred to sterile centrifuge tubes, pelleted by centrifugation at 1000 × g. for 3 min at 4°C, and prepared for analysis as described below.
Immunoblot analysis
A minor modification of a method described previously was used (Dorsey et al., Citation2000). After drug treatment, cells were pelleted by centrifugation, lysed immediately in buffer [1% Triton X-100, 150 mM NaCl, 2.5 mM, Tris-HCl (pH 7.2), 0.5 mM EDTA, 0.5 mM Na3VO4] supplemented with protease inhibitor cocktail (Roche Molecular Biochemicals, Germany). Protein concentration was determined using a Micro BCA kit (Beyotime Biotechnology, China). Equal amounts of proteins (60 µg) were boiled for 5 min, separated by SDS-PAGE (5% stacker and 10% resolving), and electroblotted to a nitrocellulose membrane. After blocking in TBS-T (0.1% Tween-20) and 5% milk overnight at 4°C, the blots were incubated in fresh blocking solution with an appropriate dilution of primary antibody (mouse monoclonal antibody PY20, BD Transduction Laboratories, USA) for 1 h at room temperature. Blots were washed three-times (5 min each) in TBS-T and then incubated with a 1:2000 dilution of horseradish peroxidase–conjugated secondary antibody (Santa Cruz Biotechnology, USA) for 1 h at room temperature. Blots were again washed three-times (5 min each) in TBS-T and then developed using a chemiluminescence assay (ECL-plus kit; Amersham, USA).
Results
Matrine has been proven active in regulating gene expression and cell fates in mammalian cells (Tang et al., Citation2002; Feng et al., Citation2003). In summary, the following results show that matrine can alter tyrosine protein phosphorylation and that its effects are cell-type dependent. In the bcr/abl-positive K562 cells, matrine causes both up-(proteins migrating at 220 [P220], 130 [P130], 90 [P90] and 69 [P69] kDa and down- (36 [p36] and 34 [p34] kDa) regulations. In the bcr/abl-negative Raji cells, matrine has no obvious effect for the down regulation of a protein at 36 kDa. In another bcr/abl-negative U937 cell line, matrine has no observable effects.
Effects of matrine and STI571 on tyrosine protein phosphorylation in K562 cells
shows a time-course analysis of K562 cells exposed to 0.1 mg/ml matrine. This figure reveals increases in tyrosine phosphorylation of proteins migrating at 220 (P220), 130 (P130), 90 (P90), and 69 (P69) kDa at 30 min after matrine addition and lasting for the entire experiment period. In the same cells, phosphorylations of two proteins at 36 and 34 kDa were initially down-regulated, then recovered to their corresponding control levels by 24 h. shows a dose-response study at 12 h. It revealed that in cells treated by higher concentrations of matrine, the upregulation of the above proteins declined somewhat, while the downregulation of protein at 36 and 34 kDa remained unchanged.
shows that results for K562 cells exposed to STI571 alone for 12 h. The same proteins affected by matrine showed a decrease in their tyrosine phosphorylation. The addition of matrine did not seem to affect the changes induced by STI571 alone. Alternations similar to that shown in were observed in K562 cells treated by both 0.1 mg/ml matrine and 1 µM STI571 for 12 h (data not shown).
Effects of matrine and STI571 on tyrosine protein phosphorylation in other leukemia cells
Compared to bcr/abl-positive K562 cells, bands and signals in immunobots detecting tyrosine phosphorylation of proteins from total cell lysis were significantly weaker in bcr/abl-negative Raji or U937 cells. The chimeric bcr/abl gene encodes the fusion protein P210 with constitutive tyrosine kinase activity. This aberrant bcr/abl kinase activity is the key factor contributing to the abnormal biological activity of bcr/abl-positive cells (Lugo et al., Citation1990).
In Raji cells treated by 0.1 mg/ml of matrine, tyrosine phosphorylation of protein with 36 kDa was diminished dramatically at 30 min and almost disappeared at 12 h, but elevated to the control level by 24 h. The striking decline in phosphorylation of this protein was also found in Raji cells treated with 0.2 or 0.5 mg/ml matrine for 12 h (). No other obvious effects were observed.
In the case of U937 cells treated by matrine, no obvious effects was observed (data not shown). STI571 had no observable effects on either Raji or U937 cells (data not shown).
Discussion
In a previous study, we showed that matrine induces erythroid differentiation of partial cells in K562 cell line (Zhang et al., Citation2001). The current results show that at the molecular level, matrine can alter protein tyrosine phosphorylation in these cells. However, the mechanisms of erythroid differentiation in the K562 cell line are still unclear. One reason is that while the downstream signals engaged by bcr/abl expression are common to a number of oncogenes (Ras, MAPK, PI3K, AKt) (Puil et al., Citation1994; Shorski et al., Citation1995Citation1997; Cortez et al., Citation1997), the reported signal pathways involved in the erythroid differentiation of K562 cells induced by different chemical compounds may be distinct. For example, the hemin-induced erythroid differentiation pathway has been reported to be accompanied by reduction in levels of tyrosine-phosphorylated proteins (Richardson et al., Citation1987) while, to the contrary, butyrate induces both dose and time-dependent tyrosine phosphorylation of several proteins, which can be blocked by the tyrosine kinase inhibitor genistein (Rivero et al., Citation1996). The designed small molecule STI571, and inhibitor of the bcr/abl protein, can also induce K562 cells toward erythroid differentiation as well as significant apoptosis (Fang et al., Citation2000; Jacquel et al., Citation2003). This pathway involves the growth factor–cytokine signaling cascades, which are also involved in normal hematopoiesis (Laneuville et al., Citation1991; Sattler et al., Citation1997). Given our current understanding of the erythroid differential process, we cannot yet provide a more detailed picture for possible connection between erythroid differentiation and changes in tyrosine phosphorylation in matrine-treated K562 cells. The data presented here strongly suggest such connections. An important future step will be to identify the exact altered proteins shown in this work.
We observed that STI571 reduces the tyrosine phosphorylation of most of the proteins examined in our experiments in K562 cells. The same compounds has no effect on Raji or U937 cells. This is consistent with the known fact that STI571, a proven effective medicine in CML therapy, acts as a specific inhibitor targeting bcr/abl. Our dose-response experiments show that the minimum required concentration of STI571 for the above effects is around 0.25 µM, similar to the reported concentration required for effective inhibition of the bcr/abl kinase activity in vitro. (Druker et al., Citation1996). This further indicates that at the molecular level, the observed effects of STI571 on K562 cells is through the direct inhibition of the kinase activity of bcr/abl.
Although both matrine and STI571 induce alterations in tyrosine phosphorylation in bcr/abl-positive K562 cells, their effects are quite distinct. Matrine upregulates tyrosine phosphorylation of some proteins while downregulating some other proteins. Only downregulation occurs after the treatment by STI571. The counterpart for this molecular level difference at the cellular level is the distinction between the cellular effects of matrine and STI571: unlike STI571, no apoptosis was observed in matrine-treated K562 cells. The difference also implies that bcr/abl kinase is not the direct molecular target of matrine.
The observed interferences between the effects of STI571 and matrine may lead to insights into their possible mechanisms. Assuming that the kinase activity of bcr/abl is the sole direct target of STI571, several possible roles of the bcr/abl protein can be hypothesized to explain the observed changes in tyrosine phosphorylation caused by matrine. First matrine may upregulate the level of bcr/abl through some unknown network of interactions, which in turn causes the observed upregulation. Second, bcr/abl may be required to activate some unknown module in the overall network, which in turn is required for the effects of matrine. Alternatively, matrine may up- or downregulate the levels of proteins that act as substrates of bcr/abl. In all cases, STI571 would block the effects of matrine, as shown in our experiments. As STI571 also blocks the downregulation effects of matrine, the first hypothesis seems unlikely, unless we assume that the hypothetical higher level of bcr/abl may cause the observed downregulations as well. Nevertheless, matrine does perturb the tyrosine phosphorylated proteins, which are of crucial importance in cellular network regulations.
The effects of matrine on the bcr/abl-negative Raji and U937 cells appears to indicate that the upregulation of protein tyrosine phosphorylation requires bcr/abl, consistent with the interferences between STI571 and matrine observed in K562 cells.
Acknowledgments
We thank Prof. Ruolan Qian (Institute of Biochemistry and Cell Biology, Shanghai, P.R. China) and Dr. Lingdi Ma (Chonqing University of Medical Sciences) for providing us with K562 and U937 cells, respectively. Raji cells were kindly provided by Dr. Xuhong Song. We thank Dr. Haiyan Liu (School of Life Sciences, University of Science and Technology of China) for critical reading of the manuscript. This work was supported by grants from the National Natural Science Foundation of China (no. 30472185) and from the Natural Science Foundation of Guangdong Province, P.R. China (no. 04106123) and from SRF for ROCS, SEM.
References
- Ai J, Gao H, He SZ, Wang L, Luo DL, Yang BF (2001): Effects of matrine, artemisinin, and tetrandrine on cytosolic [Ca2+]i in guinea pig ventricular myocytes. Acta Pharmacol Sin 22: 512–515. [PUBMED], [INFOTRIEVE], [CSA]
- Clark SS, McLaughlin J, Timmonis M, Pendergast AM, Ben-Neriah Y, Dow L, Rovera G, Smith SD, Witte ON (1988): Expression of a distinctive bcr-abl oncogene in Ph1-positive acute lymphoblastic leukemia (ALL). Science 239: 775–777. [PUBMED], [INFOTRIEVE], [CSA]
- Cortes JE, Talpaz M, Beran M, O'Brien SM, Rios MB, Stass S, Kantarjian HM (1995): Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. Cancer 75: 464–470. [PUBMED], [INFOTRIEVE], [CSA]
- Cortez D, Reuther G, Pendergast AM (1997): The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 15: 2333–2342. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Daley G, Ven Etten R, Baltimore D (1990): Induction of chronic myelogenous leukemia in mice by the p210bcr/abl gene of the Philadelphia chromosome. Science 247: 824–830. [PUBMED], [INFOTRIEVE], [CSA]
- Dhut S, Champlin T, Young BD (1990): BCR/ABL and ABL proteins: Biochemical characterization and localization. Leukemia 4: 745–750. [PUBMED], [INFOTRIEVE], [CSA]
- Ding T, Wang WR, Zhang GY, Cheng MZ, Li SH (2002): The preparing and clinical applications of complex matrine liniment. ACTA Chinese Medicine and Pharmacology (Chinese) 30: 47–48. [CSA]
- Dorsey JF, Jove R, Kraker AJ, Wu J (2000): The pyrido[2,3-d.]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 60: 3127–3131. [PUBMED], [INFOTRIEVE], [CSA]
- Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001): Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038–1042. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmerman J, Lydon NB (1996): Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med 2: 561–566. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Fang GF, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S, Bhalla KN (2000): CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 96: 2246–2253. [PUBMED], [INFOTRIEVE], [CSA]
- Feng JL, Huang GS, Zhang YQ, Wang Z, Zhang XH, Guo Y, Yan GQ (2003): Matrine effects on JM cells by inhibiting proliferation and inducing apoptosis. China J Chinese Met Med (Chinese) 28: 437–442. [CSA]
- Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001): Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876–880. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J (1990): Acute leukaemia in bcr/abl transgenic mice. Nature 344: 251–253. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jacquel A, Herrant M, Legros L, Belhacene N, Luciano F, Pages G, Hofman P, Auberger P (2003): Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation towards the erythroid lineage. FASEB J 17: 2160–2162. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E (2002): Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. J Engl J Med 346: 645–652. [CSA], [CROSSREF]
- Laneuville P, Heisterkamp N, Groffen J (1991): Expression of the chronic myelogenous leukemia-associated p21obcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line. Oncogene 6: 275–282. [PUBMED], [INFOTRIEVE], [CSA]
- Li Y, He LR (2000): Pharmacological study of Sophora. alkaloid actions on the cardiovascular system. Chinese Trad Herbal drugs (Chinese) 31: 227–229. [CSA]
- Liu J, Zhu M, Shi R, Yang M (2003): Radix Sophorae flavescentis for chronic hepatitis B: A systematic review of randomized trials. AM J Chin Med 31: 337–354. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Long Y, Lin XT, Zeng KL, Zhang L (2004): Efficacy of intramuscular matrine in the treatment of chronic hepatitis B. Hepatobiliary Pancreat Dis Int 3: 69–72. [PUBMED], [INFOTRIEVE], [CSA]
- Lozzio CB, Lozzio BB (1975): Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45: 321–334. [PUBMED], [INFOTRIEVE], [CSA]
- Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990): Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079–1082. [PUBMED], [INFOTRIEVE], [CSA]
- Ma HS, H Liu Y, Li C, Chong SY, Shun H, Feng YM, Shu MX (1996): Modulation of malignant phenotype and the immunological response of tumor cell by sophora flavescens Ait.. Chinese J Clin Oncol (Chinese) 23: 799–780. [CSA]
- Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV (2000): Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance. Blood 96: 1070–1079. [PUBMED], [INFOTRIEVE], [CSA]
- Niu KZ (1997): Pharmacology and clinical application of Sophora flavescentis.. Int J Oriental Med 22: 75–81. [CSA]
- Nowell PC, Hungerford DA (1960): A minute chromosome in human chronic granulocytic leukemia. Science 132: 1497–1501. [CSA]
- Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T (1994): Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 13: 764–773. [PUBMED], [INFOTRIEVE], [CSA]
- Qin JP, Jiang JK, Zhang Y, Wang XW (1994): Differentiation of Human erythroid leukemia K562 cells induced by Sophora flavescens extracts. J Chongqing Med Univ (Chinese) 2: 150–151. [CSA]
- Richardson JM, Morla AO, Wang JY (1987): Reduction in protein tyrosine phosphorylation during differentiation of human leukemia cell line K-562. Cancer Res 47: 4066–4070. [PUBMED], [INFOTRIEVE], [CSA]
- Rivero JA, Adunyah SE (1996): Sodium butyrate induces tyrosine phosphorylation and activation of MAP kinase (ERK-1) in human K562 cells. Biochem Biophys Res Commun 224: 796–801. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA (2002): Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 99: 10700–10705. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Sattler M, Salgia R (1997): Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Rev 8: 63–79. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B (1997): Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3K/Akt-dependent pathway. EMBO J 16: 6151–6161. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B (1995): Phosphatidylinositol-3 kinase activity in regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86: 726–736. [PUBMED], [INFOTRIEVE], [CSA]
- Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz Am, Calabretta B (1991): Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 253: 562–565. [PUBMED], [INFOTRIEVE], [CSA]
- Tang S, Cai B, Xu H, Li H, Guo S, Yang L, Lu B, Zhang L (2002): The influence of matrine on apoptosis of fibroblasts and the expression of apoptotic modulation related protein in hypertrophic scar of rabbit ear. Chinese J Burns (Chinese) 18: 299–301. [CSA]
- Xu XR, Jiang JK (1998): Recent progress in anticancer bioactivity study of Sophora flavescens. and its alkaloids. Chinese J Integrated Trad Chinese Western Med (Chinese) 4: 235–239. [CSA]
- Zhang YL (1996): Clinical study on matrine for the treatment of psoriasis. Hebei J Med Sci (Chinese) 69: 590–591. [CSA]
- Zhang LP, Jiang JK, Tam JW, Zhang Y, Liu XS, Xu XR, Liu BZ, He YJ (2001): Effects of matrine on proliferation and differentiation in K-562 cells. Leuk Res 25: 793–800. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Zhang BH, Wang NS, Li XJ, Kong XJ, Cai YL (1990): Anti-arrhythmic effects of matrine. Acta Pharmacol Sin 11: 253–257. [CSA]
- Zhang JP, Zhang M, Zhou JP, Liu FT, Zhou B, Xie WF (2001). Antifibrotic effects of matrine on in vitro. and in vivo. models of liver fibrosis in rats Acta Pharmacol Sin 22: 183–186. [PUBMED], [INFOTRIEVE], [CSA]